Results 61 to 70 of about 581 (108)

Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study

, 2017
BACKGROUND AND OBJECTIVE: Sonidegib is a potent, selective and orally bioavailable inhibitor of the Hedgehog signaling pathway, primarily metabolized by the liver.
Liudmila, Mateva, Mateva Liudmila, Castro, Henry, Sellami, Dalila, Jocelyn Zhou, Preston, Richard A, Zhou, Jocelyn, Horsmans, Yves, Golor, George, Shibolet, Oren, George Golor, Hildegard Boss, Henry Castro, Boss, Hildegard, Emotte, Corinne, Corinne Emotte, Yves Horsmans, Quinlan, Michelle, Michelle Quinlan, Dalila Sellami, Preston, Richard A., Richard A. Preston, Oren Shibolet   +22 more
core   +1 more source

Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
This figure emphasizes current understanding of the regulatory networks, approach of diagnose, available preclinical models and clinical management of bone metastasis. to guide future therapeutic development. A deep understanding of these aspects enables the prevention of bone metastasis and the implementation of effective therapeutic strategies ...
Jingyuan Wen, Binghua Li, Shengjia Wang, Yongzhong Yao, Zhao Huang, Decai Yu   +5 more
wiley   +1 more source

Pathological Insights into the Limitations of Clinical and Dermoscopic Evaluations in Monitoring Sonidegib Treatment Response for Locally Advanced Basal Cell Carcinoma: A Real-World Study

Dermatology and Therapy
Introduction Surgical excision is the standard treatment for basal cell carcinoma (BCC). For locally advanced BCC (laBCC) not suitable for surgery or radiotherapy, Hedgehog pathway inhibitors (HHIs) such as sonidegib are important options.
Xurong Liu, Jipang Zhan, Jingwen Zou, Rongyi Chen, Jing Zhong, Renliang He   +5 more
doaj   +1 more source

Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors

Frontiers in Oncology, 2018
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma with poor prognosis. RMS frequently show Hedgehog (HH) pathway activity, which is predominantly seen in the embryonal subtype (ERMS).
Natalie Geyer, Rosalie Ridzewski, Julia Bauer, Maria Kuzyakova, Kai Dittmann, Christian Dullin, Albert Rosenberger, Hans-Ulrich Schildhaus, Anja Uhmann, Simone Fulda, Heidi Hahn   +10 more
doaj   +1 more source

Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During Treatment

Dermatology and Therapy
Introduction Sonidegib and vismodegib are Hedgehog pathway inhibitors (HHIs) approved for the treatment of locally advanced basal cell carcinoma (laBCC), as well as metastatic basal cell carcinoma (mBCC) for vismodegib.
Mark G. Lebwohl, Darrell S. Rigel, Zeynep Eroglu, Victoria E. Barghout, Deepshekhar Gupta, Enrico Zanardo, Lynn Huynh, Mihran A. Yenikomshian, Nicholas Squittieri, Thomas J. Ferro, Kunal Patel   +10 more
doaj   +1 more source

Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma

Dermatology Reports
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and its blockade represents a potential therapeutic ...
Luigi Scarpato, Marco Palla, Sabino Strippoli, Luca Tagliaferri, Luca Fania, Maristella Saponara, Anna Carbone, Francesco Spagnolo, Flavia Silvestri, Paolo Antonio Ascierto   +9 more
doaj   +1 more source

Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database

Scientific Reports
This study aims to comprehensively evaluate the long-term safety profiles of hedgehog pathway inhibitors (HPIs), sonidegib and vismodegib, which have been approved for basal cell carcinoma but lack extensive real-world safety data.
Zhixing Zheng, Zhengeng Wang, Qinghui Guo, Xiang Chen, Shuting Shen, Lixin Zhang, Enwen Lu, Zhanfa Ma, Donghui Chen   +8 more
doaj   +1 more source

Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment

Cells, 2019
The Hedgehog (Hh) pathway, containing the Patched (PTCH) and Smoothened (SMO) multitransmembrane proteins, is the main regulator of vertebrate embryonic development.
Toshiki Terao, Yosuke Minami
doaj   +1 more source

Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma

BMC Cancer
Background Following the pivotal phase II trial BOLT, the Hedgehog (Hh) inhibitor sonidegib was approved in the EU to treat locally advanced basal cell carcinoma (laBCC) in patients not amenable to surgery or radiotherapy.
Ralf Gutzmer, Ulrike Leiter, Peter Mohr, Katharina C. Kähler, Paolo Antonio Ascierto, Massimiliano Scalvenzi, Ketty Peris, Gemma María Pérez-Pastor, Ricardo Fernández-de-Misa, Rafael Botella-Estrada, Robert E. Hunger, Serena Martelli, Nur Güneli, Ramon Arntz, Axel Hauschild   +14 more
doaj   +1 more source

Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors

, 2017
Sonidegib is a selective inhibitor of Smoothened receptor, which is a key regulator of the Hedgehog signaling pathway. The purpose of this study was to determine the maximum tolerated dose based on dose-limiting toxicity (DLT) and the recommended dose ...
Minami, Hironobu;Ando, Yuichi;Ma, Brigette Buig Yue;Lee, Jih-Hsiang;Momota, Hiroyuki;Fujiwara, Yutaka;Li, Leung;Fukino, Koichi;Ito, Koji;Tajima, Takeshi;Mori, Asuka;Lin, Chia-Chi, 林家齊;李日翔   +1 more
core   +1 more source